American Heart Journal
Volume 141, Issue 6 , Pages 884-889 , June 2001

Which β-blocker for heart failure?

References 

  1. Bristow MR. Beta adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558–569
  2. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. J Cardiac Failure. 1999;5:357–382
  3. MERIT-HF Study Group . Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001–2007
  4. Packer M, Bristow MR, Cohn JN, et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–1355
  5. CIBIS Investigators and Committees . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial of beta-blockade in heart failure. Lancet. 1999;353:9–13
  6. Bristow MR. What type of β-blocker should be used to treat chronic heart failure?. Circulation. 2000;102:484–486
  7. Assmann SF, Pocock SJ, Enos LE, et al.  Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355:1064–1069
  8. Adams KF. Post hoc subgroup analysis and the truth of a clinical trial. [editorial] Am Heart J. 1998;136:751–758
  9. Davey Smith G, Egger M. Meta-analysis: unresolved issues and future developments. BMJ. 1998;316:221–225
  10. LeLorier J, Gregoire G, Benhaddad A, et al.  Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med. 1997;337:536–542
  11. Metra M, Giubbini R, Nodari S, et al.  Differential effects of beta-blocker in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102:546–551
  12. RESOLVD Investigators . Effects of metroprolol CR in patients with ischemic and dilated cardiomyopathy: the Randomized Evaluation of Strategies for Left Ventricular Dysfunction pilot study. Circulation. 2000;101:378–384
  13. Pitt B, Poole-Wilson PA, Segal R, et al.  Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial. The losartan heart failure survival study ELITE II. Lancet. 2000;355:1568–1579
  14. Cohn JN. Proceedings of the the 73rd annual meeting of the American Heart Association. In: New Orleans, La. New Orleans: The Association; 2000 Nov 15;p. 2000
  15. DiLendra A, Sabbadini G, Salvatore L, et al.  Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol. 1999;33:1926–1934
  16. Lechat P, Escolano S, Golmard JL, et al.  Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol study (CIBIS). Circulation. 1997;96:2197–2205
  17. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986;57:43F–49F
  18. Alpert NR, Mulieri LA. Human heart failure: determinants of ventricular dysfunction. Adv Exp Med Biol. 1997;430:97–108
  19. Gilbert EM, Abraham WT, Olsen S, et al.  Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817–2825
  20. Narula J, Haider N, Virmani R, et al.  Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 1996;335:1182–1189
  21. Olivetti G, Abbi R, Quaini F, et al.  Apoptosis in the failing human heart. N Engl J Med. 1997;336:1131–1141
  22. Communnal C, Singh K, Pimentel DR, et al.  Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation. 1998;98:1329–1334
  23. Communal C, Singh K, Sawyer DB, et al.  Opposing effects of beta-1 and beta-2 adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation. 1999;100:2210–2212
  24. Yoshikawa T, Port JD, Asanoo K, et al.  Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1996;17:8–16
  25. Iaccarino G, Tomhave ED, Lefkowitz RJ, et al.  Reciprocal in vivo regulation of myocardial G protein–coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade. Circulation. 1998;98:1783–1789
  26. Bohm M, Deutsch HJ, Hartmann D, et al.  Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol. 1997;30:992–996
  27. Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation. 2000;101:1634–1637
  28. Digitalis Investigation Group . The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–533
  29. Packer M, Carver JR, Rodeheffer RJ, et al.  Effects of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med. 1991;325:1468–1475
  30. Cintron G, Johnson G, Francis G, et al.  Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation. 1993;87(Suppl):VI17–VI23
  31. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis. 1998;41:39–52
  32. Engelhardt S, Hein L, Wiesmann F, et al.  Progressive hypertrophy and heart failure in beta-1 adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A. 1999;96:7059–7064
  33. Bisognano JD, Weinberger HD, Bohlmeyer TJ, et al.  Myocardial-directed overexpression of the human beta-1 adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000;32:817–830
  34. Liggett SB, Tepe NM, Lorenz JN, et al.  Early and delayed consequences of beta-2 adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation. 2000;101:1707–1714
  35. Dorn GW, Tepe NM, Lorenz JN, et al.  Low- and high-level transgenic expression of beta-2 adrenergic receptors differentially affect cardiac hypertrophy and function in G αq-overexpressing mice. Proc Natl Acad Sci U S A. 1999;96:6400–6405
  36. Rockman HA, Chien KR, Choi D, et al.  Expressions of a beta-adrenergic receptor kinase-1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A. 1998;95:7000–7005
  37. Arber S, Hunter JJ, Ross , et al.  MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell. 1997;88:393–403
  38. Milano CA, Dolber PC, Rockman HA, et al.  Myocardial expression of a constitutively active alpha1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci U S A. 1994;91:10109–10113
  39. Liggett SB, Wagoner LE, Craft LL, et al.  The Ile 164 beta-2 adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest. 1998;102:1534–1539
  40. Vincent HH. Ma in’t Veld AJ, Boomsma F, et al. Compound ICI 118,551, a beta-2 adrenoceptor antagonist, lowers blood pressure. J Hypertens. 1985;S3:S247–S249
  41. Kurz T, Richardt D, Adler S, et al.  Presynaptic effects of carvedilol in the human heart. [abstract] Circulation. 2000;102:II629
  42. Lindenfeld J, Lowes BD, Bristow MR. Hypotension with dobutamine: β-adrenergic antagonist selectivity at low doses of carvedilol. Ann Pharmacother. 1999;33:1266–1269
  43. Bristow MR, Abraham WT, Gilbert EM, et al.  Relationships between carvedilol stereoisomer plasma concentration and beta receptor occupancies in subjects with chronic heart failure in the Multicenter Oral Carvedilol Heart Failure Assessment (MOCHA). [abstract] Eur Heart J. 1996;17:135A
  44. Guillen M. Curiosity killed the lights. Five equations that changed the world. New York: Hyperion; 1995;
  45. Dunham W. Bernoulli trials. The mathematical universe: an alphabetical journey through the great proofs, problems, and personalities. New York: John Wiley; 1994;
  46. Krum H. Beta-blockers in heart failure: the ‘new wave’ of clinical trials. Drugs. 1999;58:203–210
  47. Oren RM, Ventura HO, Pina I, et al.  Prevalence of beta blocker use in heart failure clinics: report from the UNITE-HF multicenter heart failure database. [abstract] J Cardiac Failure. 2000;6:2A–79A

☆ Reprint requests: Kirkwood F. Adams, Jr, MD, Division of Cardiology, University of North Carolina at Chapel Hill, CB #7075, Burnett-Womack Building, Chapel Hill, NC 27599-7075. E-mail: kfa@med.unc.edu

☆☆ Am Heart J 2001;141:884-8.

PII: S0002-8703(01)68115-8

doi: 10.1067/mhj.2001.115583

American Heart Journal
Volume 141, Issue 6 , Pages 884-889 , June 2001

Article Tools